DIEBOLD NIXDORF INC (DBD) Fundamental Analysis & Valuation

NYSE:DBD • US2536512021

Current stock price

84.51 USD
-3.03 (-3.46%)
At close:
84.51 USD
0 (0%)
After Hours:

This DBD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. DBD Profitability Analysis

1.1 Basic Checks

  • DBD had positive earnings in the past year.
  • DBD had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: DBD reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

1.2 Ratios

  • DBD's Return On Assets of 2.45% is fine compared to the rest of the industry. DBD outperforms 64.86% of its industry peers.
  • DBD has a Return On Equity of 8.60%. This is in the better half of the industry: DBD outperforms 75.68% of its industry peers.
  • With a decent Return On Invested Capital value of 10.65%, DBD is doing good in the industry, outperforming 78.38% of the companies in the same industry.
  • DBD had an Average Return On Invested Capital over the past 3 years of 8.32%. This is significantly below the industry average of 15.19%.
  • The last Return On Invested Capital (10.65%) for DBD is above the 3 year average (8.32%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.45%
ROE 8.6%
ROIC 10.65%
ROA(3y)11.68%
ROA(5y)2.77%
ROE(3y)45.39%
ROE(5y)N/A
ROIC(3y)8.32%
ROIC(5y)6.73%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200 300

1.3 Margins

  • DBD has a Profit Margin of 2.49%. This is in the better half of the industry: DBD outperforms 67.57% of its industry peers.
  • DBD's Operating Margin of 8.79% is amongst the best of the industry. DBD outperforms 81.08% of its industry peers.
  • In the last couple of years the Operating Margin of DBD has grown nicely.
  • DBD has a Gross Margin (26.37%) which is comparable to the rest of the industry.
  • DBD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.79%
PM (TTM) 2.49%
GM 26.37%
OM growth 3Y151.18%
OM growth 5Y22.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.45%
GM growth 5Y-0.54%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DBD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DBD is creating some value.
  • DBD has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DBD has been reduced compared to 5 years ago.
  • The debt/assets ratio for DBD has been reduced compared to a year ago.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • An Altman-Z score of 2.08 indicates that DBD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • DBD has a Altman-Z score of 2.08. This is comparable to the rest of the industry: DBD outperforms 48.65% of its industry peers.
  • DBD has a debt to FCF ratio of 3.59. This is a good value and a sign of high solvency as DBD would need 3.59 years to pay back of all of its debts.
  • DBD has a better Debt to FCF ratio (3.59) than 67.57% of its industry peers.
  • A Debt/Equity ratio of 0.85 indicates that DBD is somewhat dependend on debt financing.
  • DBD has a worse Debt to Equity ratio (0.85) than 62.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 3.59
Altman-Z 2.08
ROIC/WACC1.34
WACC7.94%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B

2.3 Liquidity

  • A Current Ratio of 1.30 indicates that DBD should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.30, DBD perfoms like the industry average, outperforming 40.54% of the companies in the same industry.
  • A Quick Ratio of 0.92 indicates that DBD may have some problems paying its short term obligations.
  • DBD has a Quick ratio of 0.92. This is comparable to the rest of the industry: DBD outperforms 43.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.92
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. DBD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.93% over the past year.
  • DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 48.24% yearly.
  • The Revenue has been growing slightly by 1.46% in the past year.
  • The Revenue has been decreasing by -0.50% on average over the past years.
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
Revenue 1Y (TTM)1.46%
Revenue growth 3Y3.22%
Revenue growth 5Y-0.5%
Sales Q2Q%11.66%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.66% on average over the next years. This is quite good.
  • DBD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.76% yearly.
EPS Next Y1.85%
EPS Next 2Y11.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

6

4. DBD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 15.53, which indicates a correct valuation of DBD.
  • DBD's Price/Earnings ratio is rather cheap when compared to the industry. DBD is cheaper than 83.78% of the companies in the same industry.
  • DBD's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.71.
  • DBD is valuated correctly with a Price/Forward Earnings ratio of 15.25.
  • 67.57% of the companies in the same industry are more expensive than DBD, based on the Price/Forward Earnings ratio.
  • DBD is valuated cheaply when we compare the Price/Forward Earnings ratio to 38.09, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.53
Fwd PE 15.25
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DBD is valued cheaply inside the industry as 91.89% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, DBD is valued cheaply inside the industry as 81.08% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.17
EV/EBITDA 7.49
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • DBD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)8.41
PEG (5Y)0.32
EPS Next 2Y11.66%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DBD Dividend Analysis

5.1 Amount

  • DBD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DBD Fundamentals: All Metrics, Ratios and Statistics

DIEBOLD NIXDORF INC

NYSE:DBD (4/21/2026, 8:04:00 PM)

After market: 84.51 0 (0%)

84.51

-3.03 (-3.46%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)02-12
Earnings (Next)04-30
Inst Owners104.38%
Inst Owner Change-0.04%
Ins Owners1.57%
Ins Owner Change0.98%
Market Cap2.94B
Revenue(TTM)3.81B
Net Income(TTM)94.60M
Analysts82.86
Price Target98.6 (16.67%)
Short Float %3.38%
Short Ratio2.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.23%
Min EPS beat(2)46.39%
Max EPS beat(2)68.07%
EPS beat(4)4
Avg EPS beat(4)43.94%
Min EPS beat(4)1.76%
Max EPS beat(4)68.07%
EPS beat(8)6
Avg EPS beat(8)66.37%
EPS beat(12)8
Avg EPS beat(12)-75.33%
EPS beat(16)10
Avg EPS beat(16)-76.24%
Revenue beat(2)0
Avg Revenue beat(2)-1.02%
Min Revenue beat(2)-1.85%
Max Revenue beat(2)-0.2%
Revenue beat(4)1
Avg Revenue beat(4)-0.09%
Min Revenue beat(4)-1.85%
Max Revenue beat(4)3.02%
Revenue beat(8)3
Avg Revenue beat(8)0.08%
Revenue beat(12)4
Avg Revenue beat(12)-0.54%
Revenue beat(16)4
Avg Revenue beat(16)-1.85%
PT rev (1m)0%
PT rev (3m)22.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.73%
EPS NY rev (1m)0%
EPS NY rev (3m)12.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.13%
Valuation
Industry RankSector Rank
PE 15.53
Fwd PE 15.25
P/S 0.77
P/FCF 11.17
P/OCF 9.78
P/B 2.67
P/tB N/A
EV/EBITDA 7.49
EPS(TTM)5.44
EY6.44%
EPS(NY)5.54
Fwd EY6.56%
FCF(TTM)7.56
FCFY8.95%
OCF(TTM)8.64
OCFY10.22%
SpS109.33
BVpS31.6
TBVpS-9.62
PEG (NY)8.41
PEG (5Y)0.32
Graham Number62.1892 (-26.41%)
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 8.6%
ROCE 13.48%
ROIC 10.65%
ROICexc 12.68%
ROICexgc 40.66%
OM 8.79%
PM (TTM) 2.49%
GM 26.37%
FCFM 6.92%
ROA(3y)11.68%
ROA(5y)2.77%
ROE(3y)45.39%
ROE(5y)N/A
ROIC(3y)8.32%
ROIC(5y)6.73%
ROICexc(3y)9.91%
ROICexc(5y)8.22%
ROICexgc(3y)32.13%
ROICexgc(5y)32.22%
ROCE(3y)10.53%
ROCE(5y)8.51%
ROICexgc growth 3Y61.28%
ROICexgc growth 5Y10.41%
ROICexc growth 3Y110.53%
ROICexc growth 5Y16.22%
OM growth 3Y151.18%
OM growth 5Y22.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.45%
GM growth 5Y-0.54%
F-Score7
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 3.59
Debt/EBITDA 2.03
Cap/Depr 29.33%
Cap/Sales 0.98%
Interest Coverage 5.66
Cash Conversion 65.07%
Profit Quality 278.33%
Current Ratio 1.3
Quick Ratio 0.92
Altman-Z 2.08
F-Score7
WACC7.94%
ROIC/WACC1.34
Cap/Depr(3y)20.25%
Cap/Depr(5y)18.73%
Cap/Sales(3y)0.7%
Cap/Sales(5y)0.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
EPS Next Y1.85%
EPS Next 2Y11.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.46%
Revenue growth 3Y3.22%
Revenue growth 5Y-0.5%
Sales Q2Q%11.66%
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.5%
EBIT growth 3Y159.26%
EBIT growth 5Y21.84%
EBIT Next Year56.52%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y99.77%
FCF growth 3YN/A
FCF growth 5Y25.37%
OCF growth 1Y101.54%
OCF growth 3YN/A
OCF growth 5Y21.73%

DIEBOLD NIXDORF INC / DBD Fundamental Analysis FAQ

What is the fundamental rating for DBD stock?

ChartMill assigns a fundamental rating of 5 / 10 to DBD.


What is the valuation status of DIEBOLD NIXDORF INC (DBD) stock?

ChartMill assigns a valuation rating of 6 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.


How profitable is DIEBOLD NIXDORF INC (DBD) stock?

DIEBOLD NIXDORF INC (DBD) has a profitability rating of 6 / 10.


Can you provide the financial health for DBD stock?

The financial health rating of DIEBOLD NIXDORF INC (DBD) is 5 / 10.


What is the earnings growth outlook for DIEBOLD NIXDORF INC?

The Earnings per Share (EPS) of DIEBOLD NIXDORF INC (DBD) is expected to grow by 1.85% in the next year.